24/7 Market News Snapshot 06 August, 2025 – BioXcel Therapeutics, Inc. Common Stock (NASDAQ:BTAI)

August 6, 2025

DENVER, Colo., 06 August, 2025 (www.247marketnews.com) – (NASDAQ:BTAI) are discussed in this article.
BioXcel Therapeutics, Inc. (BTAI) is witnessing a remarkable pre-market surge, currently trading at $3.367, representing a substantial increase of 13.37% from the previous close of $2.970. With a high trading volume of 8.33 million shares, the market reflects strong investor interest, indicative of a bullish sentiment that may lead to a potential breakout. Should this trend persist, investors might target resistance levels around $3.50, making it essential to keep an eye on volume patterns and overall market conditions to gauge future movements in BTAI stock.

In a significant development, BioXcel Therapeutics has announced the publication of a pivotal study in the peer-reviewed journal Frontiers in Pharmacology. The research, titled “Dexmedetomidine potently and reversibly regulates stress-mediated behaviors,” demonstrates the potential of BXCL501 in mitigating chronic psychiatric disorders through substantial reductions in stress-induced behaviors.

BXCL501, which has received FDA approval as IGALMI™ for the treatment of acute agitation in adults with bipolar disorder and schizophrenia, shows promising efficacy in addressing chronic stress-related conditions. The study indicates that dexmedetomidine’s mechanism of action at central alpha-2 adrenergic receptors not only alleviates agitation but may also benefit patients dealing with opioid withdrawal, acute stress disorder, and alcohol use disorder, particularly in the context of PTSD.

Notably, findings emphasize that effective doses do not impair motor skills and positively influence sleep patterns, offering significant advantages for psychiatric patients. Frank Yocca, Ph.D., Chief Scientific Officer of BioXcel Therapeutics, remarked that these outcomes validate ongoing clinical programs while paving the way for novel therapeutic applications for stress-induced behaviors. As the company continues its research, the integration of artificial intelligence in drug development further underscores its commitment to transforming mental health treatment and enhancing patient outcomes.

Related news for (BTAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.